EBS FY2025 SEC EDGAR DEF 14A #86 of 168 in industry

Emergent BioSolutions Inc. CEO pay ratio

The CEO earned $131K in FY2025 against median worker pay of $3,184 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-03-20
Industry
Chemicals & Pharmaceuticals
Industry rank
#86/168

Data updated August 2026

Subscribe to Emergent BioSolutions Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
41:1
Below Average (Scale: 0–1000:1)
CEO pay
$131K
Median worker
$3,184

Answer first

Emergent BioSolutions Inc.'s FY2025 CEO total of $131K ranks #1366 of 1,423 complete filings; its 41:1 pay ratio ranks #1051. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $3,184. Industry placement uses the FY2025 SIC-28 peer cohort (# 86 of 168, 49th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1366
$131K of 1,423 FY2025
Ratio rank
#1051
41:1 of 1,423
Industry pct
49th
below the industry median pay ratio

How Emergent BioSolutions Inc. ranks nationally

Emergent BioSolutions Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$130,553 4th percentile higher than 4% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Emergent BioSolutions Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($131K) against pay ratio (41:1) for Emergent BioSolutions Inc. (marked) and its 3 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both03398027.16796054.210194081.313592108.441.0:141.2:141.5:141.8:142.0:1CEO total payPay ratio (CEO : median worker)Emergent BioSolutions Inc., CEO total pay: 130553 · Pay ratio (CEO : median worker): 41:1Emergent BioSolutions Inc.Biocryst Pharmaceuticals Inc, CEO total pay: 12951082 · Pay ratio (CEO : median worker): 41:1Biocryst Pharmaceuticals IncRegeneron Pharmaceuticals, Inc., CEO total pay: 7313796 · Pay ratio (CEO : median worker): 42:1Regeneron Pharmaceuticals, Inc.Opko Health, Inc., CEO total pay: 1854000 · Pay ratio (CEO : median worker): 42:1Opko Health, Inc.
Emergent BioSolutions Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Emergent BioSolutions Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Emergent BioSolutions Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
41:1
FY2025
vs prior FY
-7:1
from FY2024 48:1
CEO $ YoY
+3.7%
$131K latest
Filings shown
4
FY2022–2025
Emergent BioSolutions Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $7.6M - $116,593 65:1 -
2023 $118K -98% $9,106 13:1 -52:1
2024 $126K +6.3% $2,622 48:1 +35:1
2025 $131K +3.7% $3,184 41:1 -7:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1367644, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
41:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$131K
Companies in Industry
168
vs. Industry Median
Below
#86 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Emergent BioSolutions Inc.: MODEST · MICRO pay ratio

Emergent BioSolutions Inc.'s FY2025 CEO total $131K ranks #1366 of 1,423 complete filings (lower third by dollars). the CEO earned 41× the median employee ($3,184) in FY2025.

Median employee $3,184 (LOW-MED); MODEST · MICRO stamps put about 41 median-wage years per CEO year.

CEO Total Pay

$131K

FY2025 Summary Compensation, below median

Pay Ratio

41:1

Below typical

Emergent BioSolutions Inc. in the lower-dollar third

Emergent BioSolutions Inc.'s FY2025 CEO total $131K ranks #1366 of 1,423 complete filings (lower third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Emergent BioSolutions Inc.'s $131K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1366 and ratio rank #1051 split - treat 41:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$131K
Median Employee Pay
$3,184
Pay Ratio
41:1
Filing Date
2026-03-20

Company Info

Ticker
EBS
CIK
1367644
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1367644, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Emergent BioSolutions Inc.'s FY2025 CEO total $131K ranks #1366 of 1,423 complete filings (lower third by dollars).

Read with Emergent BioSolutions Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · MICRO · LOW-MED.

Centerpoint Energy Inc · MICRO

ABS(ceo_total_comp) peer at $130K (Δ $364 lighter vs Emergent BioSolutions Inc.); MID · ELITE-MED vs this page's MODEST · MICRO · LOW-MED.
Alzamend Neuro, Inc. · MICRO

ABS(ceo_total_comp) peer at $130K (Δ $553 lighter vs Emergent BioSolutions Inc.); FLOOR · ELITE-MED vs this page's MODEST · MICRO · LOW-MED.
Delek US Holdings, Inc. · MICRO

ABS(ceo_total_comp) peer at $130K (Δ $579 lighter vs Emergent BioSolutions Inc.); MODEST · ELITE-MED vs this page's MODEST · MICRO · LOW-MED.
Schwab Charles Corp · MICRO

ABS(ceo_total_comp) peer at $131K (Δ $927 heavier vs Emergent BioSolutions Inc.); MID · ELITE-MED vs this page's MODEST · MICRO · LOW-MED.
Biocryst Pharmaceuticals Inc (SIC 28 pole)

Biocryst Pharmaceuticals Inc stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Emergent BioSolutions Inc.'s MODEST filing.
National dual ranks · #1366/#1051

Emergent BioSolutions Inc.'s FY2025 package sits #1366 by CEO dollars and #1051 by ratio under MICRO · MODEST.
Ratio primer · MODEST

Emergent BioSolutions Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Emergent BioSolutions Inc. (CIK 1367644), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.